Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR E746_T751>I
EGFR E746_T751>I - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4667
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1580
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 15329413
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Sensitivity | true |